Evidence map›Paper›PMID 38840262›Full record

ArticleEuropean journal of medical research2024

Inactivation of KDM6A promotes the progression of colorectal cancer by enhancing the glycolysis.

Dexiang Zhang, Xiaohong Zhao, Yu Gao, Meixing Wang, Mi Xiao, Kaihua Zhu, Wei Niu, Yuedi Dai

Abstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dexiang Zhang *General Surgery Department, Zhongshan-Xuhui Hospital Affiliated to Fudan University, 966th, Middle Huaihai Road, Shanghai, 200031, China.
Xiaohong Zhao *Women Health Care Department, Hainan Women and Children Medical Center, Haikou, 570312, Hainan, China.
Yu GaoDepartment of Medical Oncology, Cancer Hospital of Fudan University, Minhang, 106th, Ruili Rd., Shanghai, 200240, China.
Meixing WangDepartment of Medical Oncology, Cancer Hospital of Fudan University, Minhang, 106th, Ruili Rd., Shanghai, 200240, China.
Mi XiaoDepartment of Medical Oncology, Cancer Hospital of Fudan University, Minhang, 106th, Ruili Rd., Shanghai, 200240, China.
Kaihua ZhuGeneral Surgery Department, Zhongshan-Xuhui Hospital Affiliated to Fudan University, 966th, Middle Huaihai Road, Shanghai, 200031, China. zhukaihua.cn@gmail.com.
Wei NiuDepartment of Medical Oncology, Cancer Hospital of Fudan University, Minhang, 106th, Ruili Rd., Shanghai, 200240, China. nwniuwei@163.com.
Yuedi DaiDepartment of Medical Oncology, Cancer Hospital of Fudan University, Minhang, 106th, Ruili Rd., Shanghai, 200240, China. daiyuedi@sohu.com.

Funding

Shanghai Xuhui District Health System Peak Discipline Funding Project SHXHZDXX202304
6 · The paper itself

Abstract

KDM6A (lysine demethylase 6A) has been reported to undergo inactivating mutations in colorectal cancer, but its function in the progression of colorectal cancer has not been evaluated using animal models of colorectal cancer. In this study, we found that knocking out KDM6A expression in mouse intestinal epithelium increased the length of villus and crypt, promoting the development of AOM (azoxymethane)/DSS (dextran sulfate sodium salt)-induced colorectal cancer. On the other hand, knocking down KDM6A expression promoted the growth of colorectal cancer cells. In molecular mechanism studies, we found that KDM6A interacts with HIF-1α; knocking down KDM6A promotes the binding of HIF-1α to the LDHA promoter, thereby promoting LDHA expression and lactate production, enhancing glycolysis. Knocking down LDHA reversed the malignant phenotype caused by KDM6A expression loss. In summary, this study using animal models revealed that KDM6A loss promotes the progression of colorectal cancer through reprogramming the metabolism of the colorectal cancer cells, suggesting that restoring the function of KDM6A is likely to be one of the strategies for colorectal cancer treatment.

Indexed as

Colorectal NeoplasmsDisease ProgressionGlycolysisHistone DemethylasesAnimalsCell ProliferationGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMiceHistone DemethylasesHypoxia-Inducible Factor 1, alpha SubunitKDM6A protein, humanUtx protein, mouseCancer metabolismColorectal cancerKDM6ALDHA

Identifiers

PMID38840262
PMCPMC11155098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.